Constantiam Biosciences

Constantiam Biosciences is a biotechnology company that develops precision medicine platforms designed to improve the interpretation of human genetic variation. The company specializes in integrating massively multiplexed functional genomics experiments—specifically Multiplexed Assays of Variant Effect (MAVEs)—with human biobank data using probabilistic machine learning. Its primary technologies include Varify, a statistical analysis platform for reclassifying Variants of Uncertain Significance (VUS) at scale, and MAVEvidence, a user-facing application for automated data presentation and evidence report generation. By leveraging these tools, the company aims to enhance the accuracy of genetic testing and streamline drug discovery processes.

These platforms are designed to address the challenges faced by genetic testing laboratories and pharmaceutical developers, who often struggle to interpret the clinical significance of rare genetic variants. By providing clearer, high-confidence insights into variant effects, Constantiam’s solutions aim to improve patient diagnoses, support better clinical trial stratification, and accelerate the development of precision therapies. The company has been supported by funding from the U.S. National Human Genome Research Institute (NHGRI) through Small Business Innovation Research (SBIR) grants to advance its functional genomics and analytical capabilities.